



Date: 13.02.2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051
NSE SYMBOL: MKPL

Sub: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, February 13, 2025, *inter alia*, considered and approved the Un-Audited Financial Results for the quarter and nine months ended December 31, 2024 along with the Limited Review Report thereon by the Statutory Auditors of the Company.

A copy of the Un-Audited Financial Results along with Limited Review Report of the Auditors is attached herewith as Annexures.

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 05:40 P.M. You are requested to take the same on your record.

Thanking You,

**Yours Sincerely,
FOR M K PROTEINS LIMITED**

**Neha Aggarwal
Company Secretary cum Compliance Officer**

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To,
The Board of Directors,
M. K. Proteins Limited
Naraingarh Road, Village Garnala,
Ambala City (Haryana), India - 134003

Ref : **Limited Review Report of Unaudited Standalone Financial Results for the quarter ended 31st December, 2024 and year to date from 1st April, 2024 to 31st December, 2024**

1. We have reviewed the accompanying statement of unaudited quarterly standalone financial results of **M. K. Proteins Limited** ("the Company") for the quarter ended December 31, 2024 and year to date from 1st April, 2024 to 31st December, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies [Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Company does not have any subsidiary/associate/joint venture company(ies) as on December 31, 2024

Place: New Delhi

Date: 13th February 2025

For KRA & Co.,
Chartered Accountants
Firm Registration No. 020266N



RAJAT GOYAL
(PARTNER)
Membership No.: 503150
UDIN: 25503150BMJBVG7932

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Gamala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01021

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2024

(Rs. In Lacs)

	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED	
	31-12-2024 (UNAUDITED)	30-09-2024 (UNAUDITED)	31-12-2023 (UNAUDITED)	31-12-2024 (UNAUDITED)	31-12-2023 (UNAUDITED)	31-03-2024 (AUDITED)	31-03-2023 (AUDITED)
1. Revenue							
a) Revenue from Operation (Net)	3947.88	3369.01	6886.26	13050.19	15869.82	24557.11	31486.00
b) Other Income	24.56	21.16	0.64	45.72	3.62	44.66	55.35
Sub-Total "1"	3972.44	3390.17	6886.90	13095.91	15873.44	24601.77	31541.35
2. Expenditure							
a) Cost of Material Consumed	2003.69	882.10	5736.72	5445.04	9427.33	20571.80	25574.42
b) Purchase of Stock-in-Trade	1968.15	430.17	598.33	2806.28	2935.66	3294.36	4912.19
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(472.85)	1638.89	(124.37)	3322.95	1761.99	(2223.11)	(1967.95)
d) Employees Benefits Expenses	63.97	62.28	63.47	192.03	199.54	278.80	177.06
e) Manufacturing, Operating and Other Expenses	205.26	131.92	256.46	506.64	725.94	973.61	1080.47
f) Finance Costs	6.92	3.32	10.71	43.06	66.72	106.49	184.16
g) Depreciation and Amortization Expenses	11.43	7.48	11.74	26.32	35.09	52.85	82.02
Sub-Total "2"	3786.57	3156.16	6553.06	12342.32	15152.27	23054.80	30042.37
3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 – 2]	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before Extraordinary items and Tax [3 – 4]	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
6 Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) before Tax [5 – 6]	185.87	234.01	333.84	753.59	721.17	1546.97	1498.98
8 Tax Expenses							
a) Provision for Current Tax	47.40	58.43	83.58	190.32	181.58	417.73	399.52
b) Provision for Deferred Tax Liability/(Adjustment)	0.95	1.10	2.30	3.14	1.38	8.05	6.00
c) Prior Year Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub-Total "8"	48.35	59.53	85.88	193.46	182.96	425.78	405.52
9 Profit/(Loss) for the Period from continuing operations [7 - 8]	137.52	174.48	247.96	560.13	538.21	1121.19	1093.46
10 Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/(Loss) for the period [9 + 12]	137.52	174.48	247.96	560.13	538.21	1121.19	1093.46
14 Other Comprehensive Income net of taxes							
a) (i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.55)	0.79
(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.14)	0.20
b) (i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub- Total "14"	0.00	0.00	0.00	0.00	0.00	(0.41)	0.59
15 Total comprehensive Income for the Period [13 + 14]	137.52	174.48	247.96	560.13	538.21	1120.78	1094.05
16 Earnings per share							

a)	Earnings per Equity Share for continuing operations							
	Basic earnings/(Loss) per share from continuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
	Diluted earning/(Loss) per share from continuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
b)	Earnings per Equity Share for discontinuing operations							
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share							
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.04	0.04	0.20	0.15	0.43	0.30	8.74
17	Details of Equity Share Capital							
	Paid-up Equity Share Capital	3753.72	3753.72	1251.24	3753.72	1251.24	3753.72	1251.24
	Face value of Equity Share Capital	1	1	1	1	1	1	10
18	Other Equity [Reserves]	-	-	-	-	-	2353.84	3735.19

Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13th February, 2025.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. As on 31st December 2024, the Company does not have any Associate, Subsidiary or Joint Venture Company.

For and on behalf of the board



Parmod Kumar
Managing Director
DIN: 00126965

Place: Ambala
Dated: 13-02-2025